MicroAbstract
Imatinib has been the standard of care in chronic myelogenous leukemia for fifteen years. Its optimal plasma concentration correlates with optimal disease response. We compared plasma concentrations in patients who switched from branded to generic imatinib. No statistical difference in achieved imatinib plasma concentrations was found, and the treatment response was maintained.
Introduction
Since 2001, imatinib improved prognosis in chronic myelogenous leukemia (CML) 1 and is the standard of care worldwide. Recently, imatinib generics became available. Some case reports/series [2] [3] [4] [5] [6] raised concerns about its efficacy but refer to generics with questionable bioequivalence. 7 To date, there is no evidence that imatinib generics approved in North America and the European Union (EU) lack efficacy compared to the branded drug, even when comparing different imatinib crystal forms. 7 Several studies correlated imatinib plasma concentrations (IPC) with adequate treatment response. [8] [9] [10] Recommended therapeutic imatinib plasma concentration (IPC) is between 1000 µmol/L and 3000 µmol/L. Small intra-patient variations, greater inter-patient variation,
proportional dose-exposure relationship, and therapeutic concentration interval are basic imatinib properties making it suitable for therapeutic drug monitoring (TDM). 11 Our institution standard operating protocol does not require regular screening IPC monitoring except in cases of unmet optimal treatment goal at respective time points according to ELN criteria. 
Patients and Methods

Study design
IPC was measured in 24 consecutive CML patients in their first chronic phase running out their last branded imatinib prescription. Their prescriptions were refilled with one of the available generics by our institution pharmacy. Afterward, branded imatinib was changed to one of the available generics or both consecutively. IPCs were measured every time the change in prescription was made. All drugs were used in an equivalent dose of 400 mg po qd for at least one month before IPCs were measured. Patients were interviewed for adherence to regular imatinib use. During the study, no relevant changes in other chronic therapy were recorded.
Blood sampling and analytical methods
High-performance liquid chromatography (HPLC) was used to determine imatinib plasma concentration from a peripheral blood specimen collected 21-24 hours after the last dose.
The test was performed without delay or pooling the samples. 
Results
Study population characteristics
Twenty-four patients who changed from branded imatinib to generics with a median age of 49 years (range 22-76) were enrolled in the trial. Fifteen of them (63%) were male. Branded imatinib was changed to Neopax (11 patients), or Imakrebin, either from Glivec or Neopax, at some time point (18 patients). There were no statistical differences between the patients using corresponding imatinib when grouped by gender (p=0.935), age (p=0.698), or adherence (p=0.166). The analysis was also done for the IPCs in the same patients while on corresponding compounds, grouped based on the following compound changes: Glivec to Neopax (6 patients), Glivec to Imakrebin (13 patients), and Glivec to Neopax to Imakrebin, consecutively (5 patients). The groups were comparable by gender (p=0.546) and age (p=0.701). Five patients in the group whose prescriptions were refilled only with Imakrebin reported suboptimal adherence. Nevertheless, the difference did not reach statistical significance (p=0.059). Table 1 summarizes the patient's demographics and adherence characteristics.
Imatinib plasma concentrations and treatment response
The baseline median IPC achieved with branded imatinib was 1454 µmol/L (range 485-2706) with 21 and 3 patients achieving major molecular response (MMR) and complete cytogenetic response (CCyR), respectively. Eighteen patients (75%) had IPC ≥ 1000 µmol/L. Suboptimal IPCs were measured in 5 patients with poor adherence. Later on, they improved compliance (see Table 2 ). Patient no. 12, who reported good adherence, had suboptimal IPCs regardless of the drug he was using. Since he did not meet optimal treatment goals at the recommended time point, imatinib dose was increased to 600 mg due to his enormous body surface area. After six months, he achieved major molecular response (MMR). Eleven patients (10 with MMR and 1 with CCyR) were using Neopax and achieved with it median IPC of 1716 (1249-3630) µmol/L. All of them maintained optimal disease response while using Neopax. Eighteen patients, while using Imakrebin at some time point after Glivec or Neopax, had a median IPC 1458 (707-2880) µmol/L and maintained optimal disease response. Of all 24 patients, 16 (89%) had IPC ≥ 1000 µmol/L while using any of three compounds.
Univariate analysis
Achieved median IPCs with all three compounds were compared in univariate analysis.
Although median IPC achieved with Neopax was higher, and greater inter-patient difference of IPCs was observed, it was statistically insignificant (p>0.257, Figure 1 ). Suboptimal IPCs were measured in 33% of patients while using Glivec, 13% of patients while using Imakrebin, and none while using Neopax (p=0.161, Figure 2 ). Suboptimal adherence was associated with suboptimal IPCs while using Glivec (p=0.006). The same association was not observed in patients while using Imakrebin (p=0.490) or Neopax (no observed suboptimal adherence nor IPCs). 
Discussion
In our study, both imatinib generics in equivalent doses achieved adequate IPCs in most of the enrolled patients (100% and 89%). All patients maintained a good therapeutic response achieved with the branded drug. Both generics were well tolerated, and there was no recorded discontinuation due to adverse effects. These results suggest comparable efficacy and a safety profile of examined generics to branded imatinib. Moreover, the presented data demonstrate interchangeability of different imatinib generics. As expected, adherence stays an important issue in treatment with imatinib.
For CML patients in Croatia, imatinib is in total reimbursed by the Croatian Health Insurance
Fund. The cost of 400 mg qd dosage of branded imatinib after generics became available, is now maintained between $37,200 and $31,200 per year, depending on US Dollar/Croatian Kuna (HRK) currency. Since the price of the first approved generic cannot cross the limit set at 80% of the price of the branded drug, and the price of all other generics is limited to 90%
of the price of the first generic, by default, all generic drugs should be cheaper than the patented predecessor. 14 The introduction of several new imatinib generics resulted in continuous price reductions making treatment costs as low as $12,000 annually. In the public health system, prescriptions for imatinib are only renewed in public hospital pharmacies that are supplied with it in the process of public procurement. Competing for their interests, pharmaceutical companies offer discounts that, in turn, lead to additional cost reductions.
Because of that, the cost of imatinib generic can be more than five times cheaper than the branded imatinib. Availability of generic imatinib is expected to reduce treatment costs worldwide. However, its price is subject to the healthcare system organization, geopolitical and socioeconomic conditions of the particular country or region. 
